- Journal List
- Elsevier - PMC COVID-19 Collection
- PMC7357506
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Radiother Oncol. 2020 Oct; 151: 15–16.
Published online 2020 Jul 13. doi:10.1016/j.radonc.2020.07.021
PMCID: PMC7357506
PMID: 32673779
Kathy Han,a,b,⁎ Lucas Mendez,c David D'Souza,c Vikram Velker,c Elizabeth Barnes,e,b Michael F. Milosevic,a,b Anthony Fyles,a,b Sarah E. Ferguson,a,d Amandeep Taggar,e,b Jennifer Croke,a,b Elysia Donovan,e,b and Eric Leunge,b
Author information Article notes Copyright and License information PMC Disclaimer
Associated Data
- Supplementary Materials
Dear Editor:
The COVID-19 pandemic has dramatically impacted surgical capacity, radiotherapy and chemotherapy delivery worldwide. Contributing factors include the importance of social distancing to reduce viral transmission, the recognition that cancer patients have a higher risk of severe events compared to non-cancer patients [1], and resource limitations of the cancer centre with limited personal protective equipment (PPE), staffing shortages due to illness and redeployment. Recommendations have been made by national bodies and individual institutions to defer adjuvant RT, and to hypofractionate adjuvant and definitive treatment where appropriate [2], [3], [4].
Radiotherapy has an important and established role in the primary and adjuvant management of gynecologic cancers. It is the definitive treatment modality for locally advanced cervical, vaginal, and vulvar cancers. Adjuvant radiotherapy may be recommended for endometrial, cervical, vaginal and vulvar cancers. While the volume of patients referred for adjuvant radiotherapy may have decreased during the pandemic with reduction in operation room hours, there conversely may be an increased demand for radiotherapy for cancers traditionally managed with upfront surgery, or progressed during the pandemic.
We would like to share our approaches earlier on during the pandemic with the broader community. As radiation oncologists specializing in gynecological cancer management at three large academic cancer centers in Southern Ontario, Canada, we participated in separate multi-disciplinary (with gynecologic and/or medical oncologists) at our institutions and cross-institutional meetings with each other between March – early April 2020 for COVID-19 pandemic planning. The radiation oncology group searched the literature on hypofractionated, abbreviated and alternative radiotherapy regimens, as well as impact on the delay of radiation treatment using National Library of Medicine (PubMed/MEDLINE). We established potential strategies based on the existing literature, prioritizing prospective data and randomized controlled trial where available (Supplementary material). Where multiple modalities are employed, the relative and/or incremental benefit of each modality was considered. We employed evidence-based strategies where possible for radiation treatment of gynecologic cancers during the COVID-19 pandemic, with a view towards treatment deferral and/or reduced number of fractions whenever feasible and appropriate. In general, we prioritized newly diagnosed or isolated loco(regional) recurrent, curable gynecological cancer where radiotherapy is the primary curative modality, such as locally advanced cervical, vaginal and vulvar cancer, and isolated vaginal recurrence of endometrial cancer. Every effort was made to minimize the overall treatment time of locally advanced cervical cancer, including the use of simultaneous integrated nodal boost and not delaying 3D image-guided brachytherapy during the pandemic. While the numbers of COVID-19 cases have been declining in several countries (including Canada), they continue to surge in others where our approaches may be of interest.
Footnotes
☆The Editors of the Journal, the Publisher and the European Society for Radiotherapy and Oncology (ESTRO) cannot take responsibility for the statements or opinions expressed by the authors of these articles. Practitioners and researchers must always rely on their own experience and knowledge in evaluating and using any information, methods, compounds or experiments described herein. Because of rapid advances in the medical sciences, in particular, independent verification of diagnoses and drug dosages should be made. For more information see the editorial “Radiotherapy & Oncology during the COVID-19 pandemic”, Vol. 146, 2020.
Appendix ASupplementary data to this article can be found online at https://doi.org/10.1016/j.radonc.2020.07.021.
Appendix A. Supplementary data
The following are the Supplementary data to this article:
Supplementary Data 1:
Click here to view.(147K, docx)
References
1. Yu J., Ouyang W., Chua M.L.K., Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan. China. JAMA Oncol. 2020;6(7):1108–1110. [PMC free article] [PubMed] [Google Scholar]
2. Filippi A.R., Russi E., Magrini S.M., Corvò R. Letter from Italy: First practical indications for radiation therapy departments during COVID-19 outbreak. Int J Radiat Oncol Biol Phys. 2020;107(3):597–599. [PMC free article] [PubMed] [Google Scholar]
3. Coronavirus (COVID-19): cancer treatment documents. Royal College of Radiologists (RCR). https://www.rcr.ac.uk/college/coronavirus-covid-19-what-rcr-doing/coronavirus-covid-19-resources/coronavirus-covid-19-1. [accessed 6 April 2020].
4. Coles C.E., Aristei C., Bliss J., et al. International Guidelines on Radiation Therapy for Breast Cancer During the COVID-19 Pandemic. Clinical Oncology. 2020;32:279–281. [PMC free article] [PubMed] [Google Scholar]
Articles from Radiotherapy and Oncology are provided here courtesy of Elsevier
